News | July 09, 2010

Lantheus Medical, MDS Nordion to Produce More of Medical Isotope

July 9, 2010 – Lantheus Medical Imaging Inc. announced this week that it has signed a new manufacturing and supply agreement with MDS Nordion to purchase molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m). Mo-99 is used in Lantheus Medical Imaging’s TechneLite generators, which are sold throughout the world, and which produce Tc-99m, a medical isotope widely used in nuclear medicine imaging.

Under terms of the new agreement, Lantheus will begin receiving additional supplies of Mo-99 on a weekly basis once the National Research Universal (NRU) reactor is back online, which is currently anticipated to be at the end of July 2010. The contract is in place until July 31, 2011.

“Our agreement with MDS Nordion is part of Lantheus Medical Imaging’s aggressive supply chain strategy to strengthen our Mo-99 supply by working with major suppliers around the world in helping to meet the medical isotope needs of our customers in North America,” said Don Kiepert, president and chief executive officer, Lantheus Medical Imaging Inc.

“This agreement represents MDS Nordion and Lantheus’ commitment to provide medical isotopes to the global nuclear medicine community,” said Steve West, chief executive officer, MDS Inc. “The Nordion team has been actively preparing for the NRU restart and we have taken the steps necessary to assume our role in the supply chain and resume the processing of isotopes for patients worldwide.”

Over 21 million doses of diagnostic radiopharmaceuticals were injected into patients in the United States during 2009. Of these, 65 percent were for cardiac exams, with the remaining for oncology, neurology and other applications. Tc-99m, which is the decay product of Mo-99, is the most commonly used medical radioisotope in the United States. At 16.7 million doses, Tc-99m accounted for 80 percent of all diagnostic radiopharmaceutical injections.

Tc-99m is used in Lantheus Medical Imaging’s TechneLite generators, which are distributed to radiopharmacies and hospitals as a source of Tc-99m for diagnostic imaging procedures. In diagnostic use, the Tc-99m is attached to a specific molecule and injected into the patient. The diagnostic medicine then travels to the site or organ of interest and a special camera is used to pick up the gamma rays emitted from the radioactive material in the body and to create images for diagnostic evaluation.

Related Content

Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...

While subject No. 1 (left) was judged as positive for both the neuronal injury and the amyloid load biomarker, both Alzheimer's disease biomarkers were negative in subject No. 2 (right). Image courtesy of Henryk Barthel et al., University Hospital Leipzig, Leipzig, Germany

News | PET Imaging | June 14, 2017
More people die of Alzheimer's disease than prostate and breast cancer combined. Identifying the disease before major...
News | Clinical Study | June 09, 2017
The milestone Imaging Dementia — Evidence for Amyloid Scanning (IDEAS) Study is working with government and academic...
advanced visualization
News | Molecular Imaging | June 09, 2017
The Food and Drug Administration (FDA) has cleared syngo.via VB20 for Molecular Imaging (MI) from Siemens Healthineers...
News | SPECT-CT | June 08, 2017
Siemens Healthineers debuts Symbia Intevo Bold at the 2017 annual meeting of the Society of Nuclear Medicine &...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
May 22, 2017 — Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced t
Overlay Init